Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 709-716

  Järbrink, Krister ^a   Kreif, Noemi ^b   Benedict, Agnes ^b   Locklear, Julie ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Antipsychotics; Costs; Quality of life; Quetiapine XR; Schizophrenia; Switch

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; WEIGHT GAIN;

EID: 67649399001     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902738810     Document Type: Article

References (18)

1. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-165 (Pubitemid 39209485)
2. Mangalore R, Knapp M. Cost of schizophrenia in England. J. Ment Health Policy Econ 2007;10:23-41 (Pubitemid 46613421)
3. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-293 (Pubitemid 38828535)
4. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomised, controlled trials. Am J Psychiatry 2003;160:1209-1222 (Pubitemid 41070936)
5. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8
6. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415-427 (Pubitemid 46513155)
7. Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006;354:518-520 (Pubitemid 43200304)
8. Ganesan S, Agambaram V, Randeree F, et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008;24(1):21-32 (Pubitemid 351160235)
9. Lenert LA, Rupnow MFT, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes 2005;3:57-64 (Pubitemid 41522350)
10. Barnes TRE. A rating scale for drug-induced akathisia (BARS). Br J Psychiatry 1989;154:672-676 (Pubitemid 19154942)
11. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl. 44):11-19
12. British National Formulary: RPS Publishing. Available at: http://www.bnf.org [Last accessed 8 January 2008]
13. Lfn.se [Läkemedelsförma° nsnämnden]. Available at: http://www.lfn.se [Last accessed 28 January 2008]
14. Sekretariat der Roten Liste GmbH: Rote Liste Online. Available at: http://www.roteliste.de [Last accessed 1 February 2008]
15. Číselníky. Hromadně vyrábě né léčivé přípravky a potraviny pro zvláštní lékařské účely. Účinnost od 1. května 2007, verze 621. Praha: Všeobecná zdravotní pojišťovna České republiky; 2007
16. Farmadati Italia s.r.l. Compendio Farmaceutico Telematico, 2007
17. Oanda.com. The currency site. Available at: http://www.oanda.com [Last accessed 12 March 2008]
18. Kahn RS, Schulz C, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:832-842 (Pubitemid 47015481)